Global $6.13 Billion CAR-T Cell Therapy Markets, 2017-2020 & 2021-2026: Focus on Yescarta, Kymriah, Tecartus, Breyanzi, Abecma, Others
28 sept. 2021 04h28 HE
|
Research and Markets
Dublin, Sept. 28, 2021 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Markets, Competition Forecast & Opportunities, 2021-2026" report has been added to ResearchAndMarkets.com's offering. ...
Global CAR-T Cell Therapy Market Research Report 2021: Approvals of Kymriah and Yescarta in Multiple Regions to Further Push Market Growth
21 sept. 2021 04h23 HE
|
Research and Markets
Dublin, Sept. 21, 2021 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen; By Indication; By Regions: Segment Forecast, 2021 - 2028"...
Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK
16 sept. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
15 sept. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Monthly information on share capital and company voting rights
10 sept. 2021 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 ...
Autolus Therapeutics to participate in upcoming virtual investor conferences
02 sept. 2021 07h00 HE
|
Autolus Therapeutics plc
- Goldman Sachs Eleventh Annual Biotech Symposium on September 7- 2021 Virtual Wells Fargo Healthcare Conference on September 10 at 7.30am ET - H.C. Wainwright & Co 23rd Annual Global Investment...
Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology
01 sept. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
09 août 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress
05 août 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer
15 juil. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...